{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:35Z","timestamp":1761238295607},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:p>Confronted with the different clinical impacts of different treatments, the rising cost of cancer care, and the financial burden of high drug prices, several influential professional organizations have developed models with which to assess the clinical benefit and value of cancer treatment regimens. The goal is a system of valuing patient therapies that is aligned with the beneficial impact to the patient and society and that moves away from a fixed cost regardless of clinical circumstances.<\/jats:p>","DOI":"10.1634\/theoncologist.2016-0177","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T03:39:15Z","timestamp":1464752355000},"page":"654-658","source":"Crossref","is-referenced-by-count":33,"title":["New Frameworks to Assess Value of Cancer Care: Strengths and Limitations"],"prefix":"10.1093","volume":"21","author":[{"given":"Lowell E.","family":"Schnipper","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Bastian","sequence":"additional","affiliation":[{"name":"GfK Market Access, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"2021122309534131600_B1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122309534131600_B2","volume-title":"USA Today, Kaiser Family Foundation, Harvard School of Public Health: National survey of households affected by cancer"},{"key":"2021122309534131600_B3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.amjmed.2009.04.012","article-title":"DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: Results of a national study","volume":"122","author":"Himmelstein","year":"2009","journal-title":"Am J Med"},{"key":"2021122309534131600_B4","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2010.33.0522","article-title":"National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008","volume":"29","author":"Bernard","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309534131600_B5","volume-title":"Kaiser Family Foundation. 2015 Employer health benefits survey","author":"Henry"},{"key":"2021122309534131600_B6","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.2011.37.9511","article-title":"Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: A population-based exploratory analysis","volume":"30","author":"Shankaran","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309534131600_B7","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1200\/JOP.2011.000418","article-title":"Understanding patients\u2019 attitudes toward communication about the cost of cancer care","volume":"8","author":"Bullock","year":"2012","journal-title":"J Oncol Pract"},{"key":"2021122309534131600_B8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2009-0307","article-title":"Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices","volume":"15","author":"Wong","year":"2010","journal-title":"The Oncologist"},{"key":"2021122309534131600_B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-156-1-201201031-00001","article-title":"Review of the American College of Physicians Ethics Manual","volume":"156","author":"Snyder","year":"2012","journal-title":"Ann Intern Med"},{"key":"2021122309534131600_B10","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309534131600_B11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122309534131600_B12","volume-title":"National Comprehensive Cancer Network"},{"key":"2021122309534131600_B13","volume-title":"Institute for Clinical and Economic Review. Methods. The ICER approach"},{"key":"2021122309534131600_B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE\u20135-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309534131600_B15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309534131600_B16","volume-title":"Memorial Sloan Kettering Cancer Center. Drug Abacus"},{"key":"2021122309534131600_B17","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122309534131600_B18","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/654\/41875498\/oncolo_21_6_654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/654\/41875498\/oncolo_21_6_654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:32:52Z","timestamp":1640320372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/6\/654\/6401428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,27]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0177","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,5,27]]}}}